ArticleOpen forum infectious diseases2023
Epidemiology, Clinical Features, and Antimicrobial Resistance of Invasive
Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Adaptive Response ofAntibiotics (Basel, Switzerland) · 2026Article
- Factors Associated With the Antimicrobial Resistance Profile of UropathogenicInterdisciplinary perspectives on infectious diseases · 2026Article
- Epidemiology of Invasive Escherichia coli Disease in Adults Using Routine Healthcare Records from the United States, 2002-2022.Infectious diseases and therapy · 2026Article
- Establishment and optimization of anFrontiers in immunology · 2026Article
- A qualitative burden of disease study in patients with invasive Escherichia coli disease aged ≥ 60 years in the United States.BMC infectious diseases · 2025Article
- A retrospective global study of the prevalence of O-serotypes of invasiveEpidemiology and infection · 2025Observational
- Economic and Disease Burden Associated with Invasive Escherichia coli Disease in the United States.Infectious diseases and therapy · 2025Article
- Risk of Invasive Escherichia coli (E. coli) Disease After Elective Urologic Procedures Among Older Adults in the United States.Infectious diseases and therapy · 2025Article
- Lineage-specific variation in frequency and hotspots of recombination in invasive Escherichia coli.BMC genomics · 2025Article
- E. Coli cytotoxic necrotizing factor-1 promotes colorectal carcinogenesis by causing oxidative stress, DNA damage and intestinal permeability alteration.Journal of experimental & clinical cancer research : CR · 2025Article
- Epidemiology of invasiveEpidemiology and infection · 2025Article
- Risk Factors and Clinical Management Strategies for Bloodstream Infections in Pediatric Hematological Malignancies.Risk management and healthcare policy · 2025Article
- Review of Antimicrobial Properties of Titanium Dioxide Nanoparticles.International journal of molecular sciences · 2024Review
- A microbiological and genomic perspective of globally collected Escherichia coli from adults hospitalized with invasive E. coli disease.The Journal of antimicrobial chemotherapy · 2024Observational
- A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI.NPJ vaccines · 2024Article
- Observational
- Article
- Progress toward a vaccine for extraintestinal pathogenicInfection and immunity · 2024Article
- Impact of Invasive Escherichia Coli Disease on Clinical Outcomes and Medical Resource Utilization Among Asian Patients in the United States.Infectious diseases and therapy · 2024Article
- Economic burden of invasiveJournal of managed care & specialty pharmacy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 13 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invasive Methods: We applied clinical criteria of systemic inflammatory response syndrome (SIRS), sepsis, or septic shock to patients hospitalized with culture-confirmed Results: Most patients with IED (N = 902) were adults aged ≥60 years (76.5%); 51.9%, 25.1%, and 23.0% of cases were community-acquired (CA), hospital-acquired (HA), and healthcare-associated (HCA), respectively. The urinary tract was the most common source of infection (52.3%). Systemic inflammatory response syndrome, sepsis, and septic shock were identified in 77.4%, 65.3%, and 14.1% of patients, respectively. Patients >60 years were more likely to exhibit organ dysfunction than those ≤60 years; this trend was not observed for SIRS. The case-fatality rate (CFR) was 20.0% (60-75 years, 21.5%; ≥75 years, 22.2%), with an increase across IED acquisition settings (HA, 28.3%; HCA, 21.7%; CA, 15.2%). Noticeably, 77.8% of patients initiated antibiotic use on the day of culture sample collection. A total of 65.6% and 40.8% of Conclusions: This study contributes valuable, real-world data about IED severity. An accepted case definition could promote timely and accurate diagnosis of IED and inform the development of novel preventative strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.